Cholangiocarcinoma

The FDA granted orphan drug designation to gavo-cel for treatment of cholangiocarcinoma.

The FDA approved ivosidenib tablets for adults with previously treated, locally advanced or metastatic IDH1-mutated cholangiocarcinoma.

The FDA granted accelerated approval to infigratinib for previously treated locally advanced or metastatic cholangiocarcinoma that harbors FGFR2 fusion or rearrangement.

The FDA granted priority review to ivosidenib tablets for patients with previously treated IDH1-mutated cholangiocarcinoma, according to the agent’s manufacturer.

Renuka Iyer, MD, received the Mark R. Clements Award for Vision, Innovation and Collaboration from the Cholangiocarcinoma Foundation.

The FDA granted breakthrough therapy designation to futibatinib for the treatment of patients with locally advanced or metastatic cholangiocarcinoma with FGFR2 gene rearrangements, according to a press release from the agent’s manufacturer.

A cholangiocarcinoma advisory board composed entirely of women has given physicians who treat the rare malignancy, as well as patients and their advocates, an opportunity to collaborate, share best practices and forge alliances.

Ivosidenib modestly extended OS among patients with previously treated isocitrate dehydrogenase 1-mutated advanced cholangiocarcinoma, according to final results of the phase 3 ClarIDHy trial presented at Gastrointestinal Cancers Symposium.

The FDA granted priority review designation to infigratinib for the treatment of cholangiocarcinoma, according to the agent’s manufacturer.

Precision medicine in cancer treatment has gained momentum due to advances in genomics and the mechanisms of targeted therapies.